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Abstract  
New psychoactive substances (NPS) have emerged worldwide in recent years, posing a threat 
to public health and a challenge to drug policy. NPS are usually derivatives or analogues of 
”classical” recreational drugs designed to imitate their effects while circumventing regulations. 
This article provides an overview of benefits and limitations of analytical screening in 
managing patients presenting with acute NPS toxicity. NPS typically cannot be analytically 
identified with the usual immunoassay tests. In order to detect NPS using an immunoassay, 
antibodies specifically binding to the new structures would have to be developed, which is 
complicated by the rapid change of the NPS market. Activity-based assays could circumvent 
this problem since no prior knowledge on the substance structure is necessary. However, 
”classical” recreational drugs activating the same receptors could lead to false positive results. 
Liquid or gas chromatography coupled with mass spectrometry is a valuable NPS analysis tool, 
but its costs (e.g. equipment), run time (results usually within hours vs. minutes in case of 
immunoasssays) and the need for specialized personnel hinder its use in clinical setting, while 
factors such as lack of reference standards can pose further limitations. Although supportive 
measures are sufficient in most cases for adequate patient management, the detection and 
identification of NPS can contribute significantly to public health and safety in cases of e.g. 
cluster intoxications and outbreaks, and to the investigation of these novel compounds’ 
properties. However, this requires not only availability of the necessary equipment and 
personnel, but also collaboration between clinicians, authorities and laboratories.   
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Introduction 
The recreational use of psychoactive substances is common; in the European Union it is 
estimated that more than 92 million or just over a quarter of 15- to 64-year-olds have used illicit 
drugs at least once in their lives [1]. In recent years, in addition to “classical” recreational drugs, 
new substances have emerged worldwide, leading to a wider range of available compounds 
than in the past [1-3]. According to the United Nations Office on Drugs and Crime (UNODC), 
NPS are defined as “new narcotic or psychotropic drugs, in pure form or in preparation, not 
controlled by either the 1961 United Nations Single Convention on Narcotic Drugs nor the 
1971 United Nations Convention on Psychotropic Substances, but which may pose a public 
health threat comparable to that presented by substances listed in these conventions” [4]. 
Based on their chemical structure and/or pharmacology NPS can be categorized into different 
classes, such as synthetic cannabinoids, also known as synthetic cannabinoid receptor agonists 
(SCRAs), synthetic opioids, phenethylamines (e.g. amphetamines including cathinones, N-2-
methoxybenzyl-phenethlylamines (NBOMes) etc.), piperazines, tryptamines, piperidines, and 
benzodiazepines. Although NPS are usually derivatives or analogues of “classical“ recreational 
drugs (Fig. 1) produced to imitate their effects while circumventing regulations, the alterations 
of their structure can have a great influence on their pharmacokinetic and pharmacodynamic 
properties even within the same class [2], thus making it difficult to predict their 
pharmacokinetics (e.g. bioavailability, elimination half-life), psychoactive effects, potency, 
and toxicity.  
The NPS phenomenon started in 2004 with the “Spice” products being sold in Western Europe 
and Japan in head-shops and via the Internet as herbal blends [5,6]. These products were 
advertised as legal alternatives to cannabis (therefore also named “legal highs”) [7]. Due to the 
availability and limited legislative control, and because they could not be detected with the 
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usual commercial drug screening methods, “Spice” became quickly popular especially among 
young people [5,7,8]. However, in 2009 Auwärter et al. could show that SCRAs (JWH-018 
and CP47,497) which had been sprayed on the leaves and not the herbal blends themselves 
accounted for the psychoactive effects of these products [5].  
Meanwhile, other NPS (over 700 substances) have also been identified. Products are often 
provided as powders and are labelled (among others) as “laboratory reagents” or “dietary 
supplements”, and with warnings such as “not for human consumption” [8]. In 2005, the 
European Union established an Early Warning System (EWS) monitored by the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and Europol. Until 2015, a rise 
of the number of newly identified substances was observed (41 NPS identified for the first time 
in 2010, 49 in 2011, 73 in 2012, 81 in 2013, 101 in 2014, 98 in 2015), with a decline seen since 
2016, (66, 51 and 55 NPS identified for the first time in 2016, 2017, and 2018, respectively) 
[1,8,9]. Nevertheless, this means that approximately one new chemical product is entering the 
illicit drug market each week.  
Some of these compounds were initially developed to study different types of receptors and are 
therefore potent agonists, exhibiting high receptor binding affinities and strong psychoactive 
effects at low doses [10,11]. For example, the phytocannabinoid Δ9-tetrahydrocannabinol (Δ9-
THC), the main psychoactive constituent of cannabis, acts as a partial agonist at the 
cannabinoid receptors 1 and 2 (CB1 and CB2), while most SCRAs are full agonists and 
generally have higher affinity for the CB1 and CB2 receptors [12,13]. Since psychoactive and 
behavioral effects are produced via CB1 agonism, this can result in greater potential for serious 
neuropsychiatric toxicity compared with cannabis. Additionally, lower doses of SCRAs are 
needed to achieve psychoactive effects, posing further difficulties associated with their 
detection.  
 
 
This article is protected by copyright. All rights reserved. 
As a further example, activation of the serotonin (5-HT) receptor 5-HT2A has been shown to 
mediate effects of hallucinogens with a strong correlation between hallucinogenic potencies in 
humans and receptor affinity in vitro [10,14-16]. The NBOMes (2,5-dimethoxy-N-
benzylphenethylamines) are serotonin 5-HT2A receptor agonists similar to other hallucinogenic 
compounds, but present a higher receptor affinity compared to phenethylamine analogues 
without an N-benzyl moiety [10,11], thus leading to stronger effects and responses, including 
fatal intoxications [17-20]. The route of consumption also varies depending on the type of NPS. 
For example, herbal blends such as “Spice” are often smoked, while tryptamines are often 
sniffed or ingested dissolved in a drink [21], and highly potent substances such as NBOMes 
are consumed sublingually on blotter paper similar to LSD [22]. 
Next to the dynamic NPS market (i.e. rapid introduction of a variety of new substances on the 
drug market in order to evade legislations) and the broad toxicological differences among the 
substances that cannot be predicted only based on the chemical structure, factors that make the 
identification and investigation of NPS difficult are related to their analytical detection in 
human samples. The immunoassays that are most commonly used at the emergency department 
(ED) of hospitals to rapidly screen for psychoactive drugs typically cannot detect NPS. 
Moreover, even more specific methods such as liquid-chromatography coupled to tandem mass 
spectrometry (LC-MS/MS) or gas-chromatography coupled to mass spectrometry (GC-MS) 
may not include the newest NPS, which can also lead to underdetection [23]. This poses 
problems for various scientists and working groups such as analytical chemists, clinical 
pharmacologists, emergency physicians, and forensic scientists trying to detect and investigate 
NPS and potential problems related to their consumption. These aspects will be discussed in 
more detail in the present article.  
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Analytics 
The approach for detection and identification of psychoactive drugs generally consists of two 
analytical steps, a preliminary screening and a confirmation test [24,25]. Since it is not feasible 
to directly test all samples with the more limited available confirmation methods, preliminary 
screening methods are used to filter presumptive positive samples and thus help to decide 
which type of subsequent confirmation method should be used for further identification [25].  
 
Samples and sample treatment  
The analysis for NPS can be performed in matrices such as blood, urine, hair, nails, oral fluid 
and tissue samples [26,27]. Urine and blood are the most commonly used samples in clinical 
setting, while the rest of the listed options are usually regarded as alternatives. Less 
conventional matrices include dried blood spots with capillary blood, which is also used for 
neonatal metabolic disease screening [28] and has recently gained more attention in clinical 
and forensic toxicology also for other applications [29-31]. Advantages of these alternative 
techniques are their longer detection time window and the less invasive sample collection and 
easier storage and shipping [29]. Usually, urine is the matrix collected for drug testing in 
clinical settings, because sampling is non-invasive, it is readily available, and has a longer 
detection window compared to blood. However, in some emergency departments sampling of 
blood might be more common because it is needed also for other analyses and patients may not 
be able/willing to provide urine. Although urine has a longer detection window and typically 
higher analyte and metabolite concentrations than blood [32], the amount of liquids consumed 
might influence the urine concentration of an analyte and due to metabolism it is possible that 
only biotransformation products (metabolites) and not the parent compound are present. For 
this reason metabolites are often included in confirmation methods. Furthermore, especially 
for substances with a long detection window a positive result does not necessarily reflect the 
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impairment at the time of the sampling. Blood has the advantage that samples cannot be easily 
manipulated and the analytical results better reflect the compounds currently present in the 
body.  
In order to protect the instruments and have better results, sample preparation is often necessary 
prior to sample analysis. The type of sample preparation technique depends on the matrix, on 
the physical and chemical properties of the investigated analytes and the level of sensitivity 
and specificity required for a certain analysis [24]. Blood samples can be extracted using 
methods such as protein precipitation, liquid-liquid extraction (LLE), salting-out assisted 
liquid-liquid extraction (SALLE), solid phase extraction (SPE) or microwave assisted 
extraction (MAE) [24,33-35]. The extraction of urine samples can be performed by SPE or 
LLE [24] but also simple dilution of the samples (dilute and shoot methods) have been reported 
[35,36]. 
 
Preliminary screening tests 
Immunoassays 
Immunoassay-based psychoactive drug screening tests are biochemical tests that use selective 
antigen-antibody binding to mostly qualitatively determine the presence of a compound [25]. 
Immunoassays can be classified into non-competitive and competitive. An example of a non-
competitive assay is a “sandwich immunoassay”, in which two different antibodies create a 
“sandwich” around the antigen. The second antibody is labelled and its amount is directly 
proportional to the amount of antigen in the sample. In a competitive assay a known amount of 
labelled antigen is allowed to compete for a limited number of binding sites, therefore, the 
amount of bound labelled antigen is inversely proportional to the amount of antigen present in 
the sample [37].  
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Qualitative immunoassays have a certain cut-off as limit of detection (which can vary 
depending on the investigated question and possible consequences, e.g. clinical vs. forensic 
setting) leading to false negative results in case of low concentrations present in the sample 
(e.g. after use of high potency drugs such as some NPS), and give in most cases either a positive 
or a negative result. However, semi-quantitative tests have also been reported [38]. For most 
substances typical immunoassay tests detect the chemical class (e.g. benzodiazepines, opiates, 
amphetamines etc.) and not a specific substance, while for some substances the specific 
substance is detected (e.g. methadone, cocaine, benzoylecgonine (cocaine metabolite), 6-
monoacetylmorphine (heroin metabolite), phencyclidine) (Table 1).  
Furthermore, immunoassays are not very specific, meaning that cross reactivity with other 
compounds with a similar structure is possible, resulting in false positive results. 
Since NPS have a high structural diversity, immunoassays typically cannot detect them or are 
too unspecific [5,7]. Thus, although SCRAs are cannabinoid receptor agonists like THC they 
are not detected by most immunoassays. Furthermore, although cathinones are amphetamines 
and differ from them only by the addition of a keto-group at the beta-carbon (Fig. 1), they are 
generally not detected by immunoassays. In contrast, some novel benzodiazepines may 
produce a positive benzodiazepine class screening test result. In order to be able to detect or 
exclude NPS using an immunoassay, further antibodies specifically binding to the new 
structures would have to be developed, which is time consuming and results in delays (thus not 
keeping up with the dynamic NPS market) and higher costs [42]. Although some actions have 
been undertaken in this direction during the last years with some immunoassays being 
developed for the detection of commonly used NPS such as some of the SCRAs [25], NPS 
immunoassays are currently clearly not part of the clinical routine. Kronstrand et al. [43] 
concluded in their evaluation of the Immunalysis Spice K2 homogenous enzyme immunoassay 
(HEIA) (Pomona, CA, USA) that an LC-MS/MS screening approach is a superior strategy to 
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immunoassays, because of the rapid change of synthetic cannabinoid structures. Similarly, 
Franz et al. [42] evaluated the diagnostic efficiency of immunoassays for screening urine for 
SCRAs and their results showed an insufficient cross-reactivity for the SCRAs available on the 
market at the time of the study and their metabolites. Furthermore, the investigated 
immunoassays had a high cut-off, which also contributed to a high proportion of false-negative 
results. Therefore, Franz et al. advised against the use of immunoassays for screening urine for 
SCRAs in clinical and forensic settings [42].  
 
Activity-based assays 
Recently, Canneart et al. [44] reported upon an activity-based assay for screening of SCRAs in 
biological samples. This assay is based on the mechanism of receptor activation combined with 
the principle of functional complementation of a split Nanoluc® luciferase [45]. Once either 
cannabinoid receptor (CB1/CB2), fused to one of the luciferase, is activated, an engineered β-
arrestin 2, fused to the other part, is recruited. The resulting restoration of luciferase activity 
leads to a measurable bioluminescence [44,45]. Therefore, SCRAs could be detected 
pharmacologically based on their cannabinoid activity. Hence, no prior knowledge on their 
structure is necessary [44,45]. However, since phytocannabinoids, although less potent, may 
also produce a positive result, conventional assays might be necessary to differentiate between 
synthetic and natural compounds (e.g. Δ9-THC) in case of positive samples [46,47]. The same 
mechanism has been used when targeting for opioid activity by activation of the µ-opioid 
receptor, and this assay has been applied successfully to 107 authentic post-mortem blood 
samples for the detection of opiates and (synthetic) opioids [48].  
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Mass Spectrometry 
Meyer and Maurer [49] concluded in their review, that only mass spectrometry (MS), after a 
variety of separation methods, provides the high level of flexibility, sensitivity and selectivity 
needed for a robust and reliable detection of NPS [26]. Chromatography coupled with MS is a 
powerful tool of analysis when it comes to whole blood, serum and urine samples. Depending 
on the molecular properties and the desired strength of separation, different methods can be 
chosen. Nowadays, liquid chromatography (LC) or gas chromatography (GC) are the most 
commonly used separation techniques in clinical settings. Using a stationary and a mobile 
phase, the chromatographic techniques separate the compounds, which can then be identified 
and quantified with the MS based on their mass-to-charge ratio.  
 
Untargeted Screening 
In recent years, untargeted screening using high-resolution mass spectrometry (HR-MS/MS) 
of urine samples has gained attention for the screening of not only “classical” but also novel 
substances, such as NPS [47]. Even though the lack of certified reference material and mass 
spectral libraries still poses a problem, the ability of HR-MS/MS to determine a compound’s 
or a fragment’s mass with sufficiently high accuracy makes it a valuable tool for the 
identification of NPS [24]. Nonetheless, this technique is specialized, time-consuming, and 
expensive and therefore not routinely available in most clinical settings. Additionally, the target 
analytes need to be present in a sufficiently high concentration in order to trigger an acquisition 
[47]. HR-MS/MS can be operated in data-independent acquisition (DIA) modes, which provide 
comprehensive full scan MS and MS/MS and qualitatively analyses of samples [24,50]. These 
techniques have the additional advantage that data can be retrospectively analysed for new 
analytes and therefore re-extraction or re-analysis of samples is not necessary [24]. 
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Additionally, it is not necessary to have a library with certified reference standards (for the 
comparison of retention times or mass spectra), thus overcoming the problem of the availability 
of NPS reference standards.  
 
Targeted Screening  
Using multi-analyte LC-MS/MS approaches such as selected reaction monitoring (SRM) 
enables the detection and (if desired) quantification of several hundred analytes in one 
chromatographic run [51]. The selectivity and number of monitored transitions defines here the 
identification power [50]. Targeted screenings are traditionally performed using low-resolution 
MS/MS devices [26] such as Qtrap instruments, which are usually routinely present in clinical 
laboratories. However, SRM methods only target analytes implemented in the method and are 
therefore not capable to detect unexpected or unknown compounds [26]. Furthermore, certified 
reference standards are needed for method development, which can pose a problem in the 
context of the dynamic NPS market. Additionally, the newest NPS may not be available or they 
may have to be obtained from other countries, which can lead to delays and problems with 
federal customs [24]. In the literature, a vast amount of LC-MS and GC-MS methods for the 
detection and quantification of NPS have been reported [52-56], including an in-depth review 
of all possible HR-MS methods for the analysis of NPS by Pasin et al. [24].  
 
Value of NPS analytics in clinical setting 
As with intoxication-related presentations in general, in cases presenting with NPS toxicity, 
decisions regarding patient management are usually based on the patient’s (or witnesses’) 
report regarding symptoms and substance(s) used and the clinical presentation (e.g. signs and 
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symptoms in accordance with a specific toxidrome). In most cases those are the first, and in 
some cases the only information available since analytical screening is not available at all 
medical facilities, and even when available, it is not necessarily performed for all intoxication 
cases or the results are not immediately available. Furthermore, other factors such as patients 
not willing to cooperate or not being able to provide a urine sample at presentation might also 
further complicate sample acquisition and can lead to delays. In line with this, in an analysis 
within the European Drug Emergencies Network (Euro-DEN) Plus project which has been 
collecting data on ED presentations due to acute recreational drug/NPS toxicity since 2013, a 
toxicological screening was routinely performed only in the minority (15%) of the cases, which 
probably reflects normal practice in most European hospitals [57]. In this study reflecting the 
real world conditions, NPS were detected only when MS methods were available and used and 
in none of the cases when only an immunoassay was used, despite reported NPS use in some 
cases [57]. Analytically detected NPS included: the phenethylamine 2,5-dimethoxy-4-
chlorphenethylamine (2C-C), the synthetic cathinones 3,4-methylenedioxypyrovalerone 
(MDPV), a-pyrrolidinopentiophenone (a-PVP), pentylone, and mephedrone, and the SCRAs 
5F-PB-22 and 5F-AKB48. Self-reported NPS included phenethylamines of the 2C- and 2D-
series compounds (2C-B, 2C-C, DOC) and NBMOes (25B-NBOMe), synthetic cathinones 
(mephedrone, methedrone, 3-methylmethcathinone (3-MMC), 4-methylethcathinone (4-
MEC)), paramethoxymethamphetamine (PMMA), benzodifurans (Bromo-DragonFLY), 
tryptamines (dimethyltryptamine (DMT)), and also products named “teenage mutant ninja 
turtle”, “devil bandit”, “charge white”, “blue ghost”. In contrast to NPS, a relatively high 
agreement between the immunoassay and the MS results was found for “classical” recreational 
substances such as methadone (100% agreement), cocaine (96% agreement), heroin (92% 
agreement), and cannabis (84% agreement) in cases for which both analytical methods were 
performed (n=213). Although these findings demonstrate the importance of additional 
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analytical methods such as MS for the detection of NPS, these methods are rarely routinely 
available, mainly due to their high costs (e.g. equipment, solvents, standards), long run time 
(results usually available within hours vs. minutes in case of immunoasssays) and the need for 
specialized personnel [57]. Less complex screening tools such as high-resolution accurate-
mass (HRAM) spectrometry using libraries that can be regularly updated from forensic 
networks can facilitate some of these aspects, but the financial barrier remains the main 
limitation regarding their use. Furthermore, as mentioned above, even specific and reliable MS 
methods cannot or may not be set-up to detect all NPS. Factors that can affect the window of 
detection (e.g. elimination half-life of the compound and its metabolites) can also lead to false 
negative results. For example, γ-hydroxybutyrate (GHB) has a short plasma elimination half-
life (20-50 minutes) that results in a short detection window (≤ 4-5 hours in blood and ≤ 12 
hours in urine) [58]. On the other hand, substances such as benzodiazepines (parent compounds 
and/or metabolites with long elimination half-lives) and cannabis can be detectable in samples 
days or even weeks after use. Therefore, management of recreational drug/NPS toxicity is 
usually based on the substances used being reported and supportive based on the clinical 
presentation (e.g. administration of benzodiazepines in case of agitation) and the detection of 
specific NPS compounds often more of scientific and epidemiologic than of immediate clinical 
practical interest. 
However, although symptomatic measures are in most NPS intoxication cases sufficient for 
adequate patient management, there are some instances where timely identification of the exact 
compound can be of public health value. For example, new NPS on the market can often lead 
to local cluster intoxications, as was the case on July 12, 2016 in New York, where 33 persons 
were exposed to an unknown drug with consequent behavioural abnormalities, described by 
bystanders as “zombielike” [59]. Using liquid chromatography-quadrupole time-of-flight mass 
spectrometry (LC-QTO/FMS), the potent synthetic cannabinoid AMB-FUBINACA (in vitro 
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85 times more potent than Δ9-THC in reference to CB1 receptor activation) [60] was identified 
in the product used and its metabolite in the serum of patients transported to local medical 
centres, thus enabling timely information of medical professionals and health authorities [59]. 
However, in line with the limitations mentioned above, the identification of the compound took 
several days, required a sophisticated MS analysis, and only the metabolite could be detected 
in patients’ samples, since due to rapid biotranformation of the parent compound, it is often not 
detectable/only at low levels present [59]. Other recent outbreaks with increased number of 
cases with severe effects following exposure to SCRAs include cases of acute kidney injury 
after use of XLR-11, agitated delirium linked to ADB-PINACA and severe illness and deaths 
associated with MAB-CHMINACA [61], and case series with other NPS compounds (e.g. 
seven analytically confirmed cases with 25I-NBOMe (clinical features included tachycardia, 
hypertension, agitation/aggression, hallucinations, seizures, hyperpyrexia, clonus, and acute 
kidney injury), identified by LC-MS/MS analysis [18]). Analytical identification of the specific 
compound in such cases, although time consuming and challenging, can significantly 
contribute to the timely detection of trends and high risk substances which has important 
implications for public health and public safety. However, this requires not only availability of 
the necessary equipment and personnel, but also collaboration between clinicians, authorities 
and laboratories, e.g. in order to timely provide adequate samples for analysis.  
Besides enabling prompt identification of trends and related health risks, analytical 
confirmation of NPS can also contribute to improving our knowledge regarding these less 
investigated substances and our understanding of the several, often unpredicted differences and 
similarities between compounds. For example, the pharmacokinetic and pharmacodynamic 
properties of SCRAs can differ considerably from the differently structured natural compound 
Δ9-THC and intoxications with these compounds are considered to be associated with a higher 
risk of adverse effects (including fatalities) and driving impairment compared to cannabis [62-
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65]. These findings are important especially in the light of the increasing interest in medical 
use of cannabis in the recent years since they contribute to the risk assessment and can be used 
to optimize patient safety and regulations (e.g. implementation of precaution measures but also 
avoidance of unnecessary restrictions) and inform about risks related to specific agents.  
In theory, the patient’s self-report could be used instead of a challenging analytical method to 
gain information about the consumed substance(s). This information in combination with a 
thorough clinical examination could facilitate linking specific effects to specific substances 
even in cases with no analytical results available. However, self-reports have several 
limitations, since NPS names are often used incorrectly (e.g. 2C-P instead of 2C-B [66]), 
patients might not know which substances they have used, and NPS use might not be reported, 
e.g. in cases of uncooperative or comatose patients, or because of fear of the legal 
consequences. Furthermore, even if reported correctly to the patient’s knowledge, the product 
information of NPS is often unreliable with products not containing what they claim and/or 
more than one compounds, and lack of consistency even among products with the same name, 
as it has been shown in studies analysing NPS products purchased online [67,68]. Therefore, 
self-reports cannot reliably replace analytical methods in order to identify use of specific NPS. 
In clinical practice, NPS will remain undetected if not reported and MS or similar analysis will 
be required to correctly identify the compound. 
 
Conclusions 
In clinical setting urine or blood samples are usually used for qualitative analysis in cases 
presenting with recreational drug/NPS toxicity, but the currently commercially available rapid 
immunoassay screening tests typically cannot identify NPS. Although in most cases, 
management is based on the patient’s self-report and clinical presentation and supportive 
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measures are sufficient, identification of specific compounds can be of public health and public 
safety value in cases of outbreaks and cluster intoxications with NPS. However, next to the 
availability of the necessary equipment and personnel, collaborations between clinicians, 
authorities and laboratories are also essential for optimizing identification of currently used 
NPS. Due to numerous limitations of self-reports more elaborated chromatographic and mass 
spectrometric methods are needed for identification and quantification of specific substances. 
However, these expensive and time-consuming methods have also limitations. Development 
of immunoassays using antibodies specifically binding to specific NPS or/and activity-based 
assays could facilitate rapid detection of some NPS in the future. Until then, chromatography 
coupled with mass spectrometry remains the most powerful and reliable tool for NPS detection 
and therefore, although of limited use in acute clinical settings, indispensable when it comes to 
forensic investigations and cases with potential legal consequences. 
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Table 1. Cut-off values for specific substances and substance classes detected with some 
commercially available immunoassays  
   Triage TOX 
Drug Screen 
(Alere) [39] 
CEDIA, DRI 
(Thermo 
Fischer) [40] 
Rapi Test 
(MD 
Doctors) 
[41] 
Substance / 
substance class 
Target Analyte Comment Cut-off 
(ng/mL) 
Cut-off 
(ng/mL) 
Cut-off 
(ng/mL) 
Amphetamine D-amphetamine Parent 1000  50 300/500/100
0 
D-
methamphetamine 
Parent 1000 50 300/500/100
0 
MDMA Parent  50 500 
MDEA Parent  50  
Barbiturates Pentobarbital Parent 300   
Secobarbital Parent   300 
Benzodiazepine Estazolam Parent 300   
Nordiazepam Metabolite  50  
Oxazepam Parent  50 200/300 
Hydroxy-
alprazolam 
Metabolite  50  
Hydroxy-
bromazepam 
Metabolite  50  
7-amino-
flunitrazepam 
Metabolite  50  
Lorazepam  Parent  50  
Cocaine Benzoylecgonine Metabolite 300 30 150/300 
Nicotine Cotinine Metabolite   100 
Opiates Morphine Parent 300 25 300/1000 
Opioids Tramadol Parent   100 
Buprenorphine Parent   10 
Methadone Parent 3000  300 
EDDP Metabolite  50 100/300 
Norfentanyl Metabolite   20 
Oxycodone Parent   100 
Propoxyphene Parent   300 
Phencyclidine Phencyclidine Parent 25  25 
Tetrahydrocann
abinol 
11-nor-9 carboxy-
Δ-9-THC 
Metabolite 50 10 20/50/150 
Ethanol Ethyl glucuronide Metabolite  100  
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Figure 1. Structural formulas of phenethylamine (basic structure) and representative 
substituted phenethylamines: the classical recreational drugs amphetamine and 
methamphetamine, and some new psychoactive substances, i.e. the synthetic cathinone 
mephedrone, the 2C-series compound 2,5-dimethoxy-4-bromophenethylamine (2C-B), the 
2D-series compounds 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-
chloroamphetamine (DOC), and the NBMOe 4-iodo-2,5-dimethoxy-N-(2-
methoxybenzyl)phenethylamine (25I-NBOMe) 
 
 
 
 
